ArticleHematology, transfusion and cell therapy2026
Association between serum biomarkers and clinical stage in treatment-naïve chronic lymphocytic leukemia.
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic lymphocytic leukemia shows significant clinical heterogeneity, highlighting the need for reliable, accessible biomarkers for staging and prognosis, especially in resource-limited settings. This study evaluates the association between inflammatory and nutritional biomarkers and clinical stage in newly diagnosed, treatment-naïve patients.
methodsA cross-sectional study enrolled 150 treatment-naïve chronic lymphocytic leukemia patients and 150 matched healthy controls at outpatient hematology clinics affiliated with Isfahan University of Medical Sciences (2024-2025). Diagnoses followed International Workshop on chronic lymphocytic leukemia 2018 criteria. Controls were confirmed healthy by peripheral blood counts, smear evaluation, and clinical examination. The Rai staging system was used. Serum biomarkers were measured at diagnosis. Statistical analysis included Analysis of Variance and Kruskal-Wallis tests, and Spearman correlation.
resultsElevated ferritin, β2-microglobulin, lactate dehydrogenase and C-reactive protein levels, erythrocyte sedimentation rate, and C-reactive protein-to-albumin ratio correlated significantly with advanced Rai stages (III-IV) (p-value <0.05) reflecting greater tumor burden and systemic inflammation. Conversely, albumin and vitamin D3 levels declined with disease severity. Ferritin and β2-microglobulin showed the strongest correlations with clinical stages, reinforcing their prognostic value.
conclusionRoutine biomarkers such as ferritin, β2-microglobulin, lactate dehydrogenase, C-reactive protein-to-albumin ratio, and vitamin D3 are strongly associated with clinical stage and disease severity in treatment-naïve chronic lymphocytic leukemia patients. Their measurement provides cost-effective, accessible prognostic tools, especially where advanced molecular testing is unavailable. Incorporating these biomarkers into clinical staging may improve early risk stratification and guide management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.